Study S003202

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

ClinicalTrials.gov record

Registration

Registration: NCT07709910
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 382
Start: 2026-07
Primary completion: 2028-11
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Participants With Obesity and Knee Osteoarthritis
Interventions: DRUG:Ribupatide Injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatment [after 68 weeks of continuous treatment, assessed every few weeks]
Percentage change from baseline in body weight after 68 weeks of treatment [after 68 weeks of continuous treatment, assessed every few weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.